The trial showed that patients randomized to chelation therapy had a lower risk of a combined endpoint of death, heart attack, stroke, percutaneous coronary intervention, bypass surgery or hospitalization for angina than those who received a placebo infusion.
FORBES: Researchers Who Ran Controversial Chelation Trial Respond to Questions